Why Radiopharma Trial Timelines Are Harder to Predict Than Traditional Oncology Trials
.png)
Why Radiopharma Trial Timelines Are Harder to Predict Than Traditional Oncology Trials
Radiopharmaceutical development is accelerating. More therapies are entering clinical trials, and more programs are advancing toward late-stage development.
But these trials do not follow the same timeline patterns as traditional oncology studies.
Timelines are harder to predict. Delays often come from factors that are not visible in standard development planning. The difference is not just in the therapy. It is in how these treatments are produced, delivered, and administered in real clinical settings.
Radiopharma Trials Operate on a Different Clock
Traditional oncology trials are typically planned around drug supply, patient enrollment, and protocol execution.
Radiopharmaceutical trials introduce an additional constraint: time.
Many radiopharmaceuticals rely on isotopes with short half-lives. Imaging agents such as ⁶⁸Ga-PSMA must be used soon after production, while therapeutic agents such as ¹⁷⁷Lu-PSMA still require coordinated preparation and delivery within defined windows [1].
This creates a level of timing sensitivity that is not common in most oncology trials. But timing alone does not explain the variability.
Delays rarely come from a single point in the system. Instead, timing constraints interact with other factors such as site readiness, imaging availability, staffing, and logistics. A delay in production can affect delivery, but its impact depends on whether the site can adjust schedules, whether imaging slots are available, and whether staff and facilities are aligned.
In practice, the “clock” is one layer of a broader system.
It introduces pressure, but variability emerges from how well that pressure is managed across the full clinical and operational workflow.
Patient Flow Is More Complex
Radiopharmaceutical trials involve more steps before treatment begins.
Patients often require imaging to confirm target expression. Some protocols include dosimetry to estimate radiation exposure. Treatment must then be scheduled across nuclear medicine, imaging, and oncology teams.
Each step requires coordination.
Regulatory guidance reflects this complexity. Agencies such as the EMA highlight the importance of imaging, dosimetry, and radiation safety in the clinical evaluation of therapeutic radiopharmaceuticals [2].
These steps are essential for patient safety and treatment effectiveness. They also introduce additional variability into trial timelines.
Site Readiness Drives Variability
Radiopharmaceutical trials depend on specialized clinical sites.
Sites must be able to handle radioactive materials, coordinate imaging and therapy, support radiation safety protocols, and operate with trained nuclear medicine teams.
Global health data shows that access to nuclear medicine and Theragnostic therapies depends on infrastructure, workforce, regulatory systems, and supply working together [3].
This directly affects timelines.
Some sites are fully prepared and can activate quickly. Others require time to establish workflows, train staff, or complete internal approvals. Even after activation, patient throughput may be limited by staffing or scheduling constraints.
This creates variability across sites and regions that is difficult to model early in development.
Delivery Models Are Still Evolving
Radiopharmaceutical therapy is advancing quickly, but clinical delivery models are still developing.
Recent literature highlights the need for specialized expertise, standardized workflows, and multidisciplinary coordination to support safe and effective expansion [4].
In practice, this means that sites do not operate uniformly.
One site may have strong imaging capabilities but limited therapy capacity. Another may have therapy capability but limited research support. Another may have both but constrained staffing.
Each site introduces a different execution profile.
Logistics Add Another Layer of Risk
Radiopharmaceutical trials depend on reliable and time-sensitive logistics.
Unlike many conventional drugs, these therapies are often produced close to the time of use and cannot be stored for extended periods. Production schedules, transport, and site readiness must align.
Global analyses of radioligand therapy highlight ongoing challenges related to infrastructure, workforce, supply, regulation, and delivery capacity [5].
Logistics are an important part of this system, but they are rarely the sole driver of delays.
In practice, logistical constraints tend to amplify other limitations. A transport delay may be manageable at a well-coordinated site but disruptive at a site with limited scheduling flexibility or staffing constraints.
This is why variability is not tied to logistics alone. It reflects how resilient the broader system is to disruption.
The System Drives the Timeline
Radiopharmaceutical trials are shaped by how well multiple systems work together.
Manufacturing, imaging, site readiness, logistics, and regulatory requirements are all interconnected. Implementation studies emphasize that these elements must be coordinated to support consistent access and delivery [6].
No single factor defines radiopharmaceutical timelines.
Variability emerges from how these constraints interact in real-world settings. A well-prepared site may absorb delays in one area, while a less coordinated environment may experience cascading effects from the same disruption.
When coordination is strong, trials can move efficiently.
When it is not, timelines become difficult to predict.
Theragnostic Insight -Radiopharmaceutical timelines are shaped by interdependent systems, not isolated constraints. Predictability improves when development strategy accounts for how these elements interact in practice.
What This Means for Sponsors and Investors
For sponsors, timeline planning must reflect real-world execution.
That includes site readiness, imaging coordination, isotope logistics, and staffing capacity. Early assessment of these factors can reduce downstream variability.
For investors, delays should be interpreted in context.
In radiopharmaceutical development, a delay does not always indicate scientific risk. It often reflects operational complexity in a system that is still scaling.
What This Means for You
Radiopharmaceutical development requires a different approach to planning.
Predictability comes from understanding how the system functions in practice, not from applying traditional oncology assumptions.
At Theragnostic Insights, we help teams identify where variability is likely to occur and build strategies that align with real clinical and operational conditions.
Because in radiopharmaceutical development, timelines are shaped by execution, not just design.
Stay tuned for more in this mini-series: Clinical Capacity Crisis: The Hidden Bottleneck in Radiopharma Development.
In the coming weeks, we’ll continue exploring the clinical capacity crisis holding back radiopharmaceutical innovation, from regional access gaps to operational gridlock and infrastructure blind spots. Don’t miss the next post as we map out the road to a truly trial-capable ecosystem.
- The Trial Site Gap: Why Radiopharmaceutical Innovation Is Hitting a Wall
- Geography Is Destiny: The Clinical Access Gaps in Radiopharmaceutical Research
- Operational Gridlock: Where Radiopharmaceutical Trials Break Down on Site
- Beyond the Badge: Rethinking What “Trial-Ready” Really Means in Radiopharma
- Infrastructure as Investment Strategy: Clinical Site Access and Radiopharma ROI
- Built for What’s Next: Redefining Clinical Site Design for Theragnostic Trials
- Speed as Strategy: How Site Scarcity Is Slowing Radiopharmaceutical Pipelines
- One Roof, Many Bottlenecks: Why Fragmented Site Models Undermine RLT Trials
- The Dosimetry Dilemma: Why Many Sites Aren’t Ready for Radioligand Trials
- Licensing & Radiation Safety: The Regulatory Maze Behind Radiopharmaceutical Trials
- The Hidden Role of Radiation Safety in Clinical Trial Activation
- The Radiopharma Workforce Gap: Who’s Actually Running These Trials?
- The Infrastructure Nobody Funds: Why Clinical Trial Sites Are Missing From Radiopharma Investment
- Manufacturing vs. Clinical Sites: The Missing Investment in Radiopharma Development
- Why Radiopharma Trial Timelines Are Harder to Predict Than Traditional Oncology Trials
References:
[1] Zhang et al., 2025. Radiopharmaceuticals and their applications in medicine. Signal Transduction and Targeted Therapy
[2] European Medicines Agency, 2024. Concept paper on the clinical evaluation of therapeutic radiopharmaceuticals in oncology. EMA
[3] International Atomic Energy Agency, 2024. Nuclear Applications in Human Health. IAEA
[4] Jacene et al., 2025. Radiopharmaceutical Therapy: Rapid Growth, Rising Challenges, and the Critical Need for Expertise. Journal of Nuclear Medicine
[5] Cancers, 2025. Radioligand Therapy in Cancer Management: A Global Perspective. MDPI
[6] Al Ibraheem et al., 2025. Implementation of Radiotheranostics: Challenges, Barriers, and IAEA Driven Strategies for Sustainable Access. Seminars in Nuclear Medicine
https://www.nature.com/articles/s41392-024-02041-6
https://humanhealth.iaea.org/resources/portfolio/nmdi-nm-in-therapy.html?
https://jnm.snmjournals.org/content/early/2025/10/23/jnumed.125.271028?
https://www.mdpi.com/2072-6694/17/21/3412?
https://www.sciencedirect.com/science/article/pii/S0001299825001102?
